Treatment with a short course of LF 15-0195 and continuous cyclosporin A attenuates acute xenograft rejection in a rat-to-mouse cardiac transplantation model

Xenotransplantation

Volumn 10, Issue 4, 2003, Pages 325-336

  Wang, Hao ^a,b,c   Hosiawa, Karoline A ^b,c   Garcia, Bertha ^c   Shum, Jeffrey B ^b   Dutartre, Patrick ^d   Kelvin, David J ^b,c   Zhong, Robert ^a,b,c  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d Laboratoires Fournier SA   (France)

Author keywords

Heart; Immunosuppression; Mice; Xenoreactive antibodies; Xenotransplantation

Indexed keywords

15 DEOXYSPERGUALIN; CD11B ANTIGEN; CYCLOSPORIN; CYCLOSPORIN A; GUANIDINE DERIVATIVE; HETEROPHILE ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOSUPPRESSIVE AGENT; LF 150195; UNCLASSIFIED DRUG;

ACUTE DISEASE; ACUTE GRAFT REJECTION; ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; BLOOD; CELL INFILTRATION; CELLULAR IMMUNITY; CHEMISTRY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FIBRIN DEPOSITION; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; GRANULOCYTE; HEART; HEART TRANSPLANTATION; HETEROTOPIC TRANSPLANTATION; HISTOPATHOLOGY; IMMUNOGLOBULIN DEPOSITION; IMMUNOHISTOLOGY; IMMUNOLOGY; MACROPHAGE; MALE; MOUSE; MOUSE STRAIN; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; RECIPIENT; SHORT COURSE THERAPY; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; THROMBOSIS; TREATMENT OUTCOME; XENOGRAFT; XENOTRANSPLANTATION;

ACUTE DISEASE; ANIMALS; ANTIBODIES, HETEROPHILE; CYCLOSPORINE; DRUG SYNERGISM; GRAFT REJECTION; GRAFT SURVIVAL; GUANIDINES; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; KILLER CELLS, NATURAL; MACROPHAGE-1 ANTIGEN; MALE; MICE; MICE, INBRED BALB C; RATS; RATS, INBRED LEW; TRANSPLANTATION, HETEROLOGOUS;

EID: 0041866772     PISSN: 0908665X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3089.2003.02038.x     Document Type: Article

References (52)

1. MCCURRY KR, KOOYMAN DL, ALVARADO CG et al. Human complement regulatory proteins protect swineto-primate cardiac xenografts from humoral injury. Nat Med 1995; 1: 423.
2. WHITE DJ, YANNOUTSOS N. Production of pigs transgenic for human DAF to overcome complement-mediated hyperacute xenograft rejection in man. Res Immunol 1996; 147: 88.
3. PLATT JL, LIN SS, MCGREGOR CGA. Acute vascular rejection. Xenotransplantation 1998; 5: 169.
4. BACH FH, WINKLER H, FERRAN C, HANCOCK WW, ROBSON SC. Delayed xenograft rejection. Immunol Today 1996; 17: 379.
5. DALMASSO AP, VERCELLOTTI GM, FISCHEL RJ, BOLMAN RM, BACH FH, PLATT JL. Mechanism of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients. Am J Pathol 1992; 140: 1157.
6. SCHAAPHERDER AF, DAHA MR, TE BULTE MT, VAN DER WOUDE FJ, GOOSZEN HG. Antibody-dependent cell-mediated cytotoxicity against porcine endothelium induced by a majority of human sera. Transplantation 1994; 57: 1376.
7. DENNERT, G. Effector mechanisms of cell-mediated immunity to xenogeneic cell antigens. J Immunol 1974; 113: 201.
8. COTTERELL AH, COLLINS BH, PARKER W, HARLAND RC, PLATT JL. The humoral immune response in humans following cross-perfusion of porcine organs. Transplantation 1995; 60: 861.
9. MCCURRY KR, PARKER W, COTTERELL AH et al. Humoral responses to pig-to-baboon cardiac transplantation: implications for the pathogenesis and treatment of acute vascular rejection and for accommodation. Hum Immunol 1997; 58: 91.
10. LIN SS, WEIDNER BC, BYRNE GW et al. The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants. J Clin Invest 1998; 101: 1745.
11. ZAIDI A, SCHMOECKEL M, BHATTI F et al. Life-supporting pig-to-primate renal xenotransplantation using genetically modified donors. Transplantation 1998; 65: 1584.
12. WATERWORTH PD, DUNNING J, TOLAN M et al. Life-supporting pig-to-baboon heart xenotransplantation. J Heart Lung Transplant 1998; 17: 1201.
13. LEVENTHAL JR, FLORES HC, GRUBER SA et al. Evidence that 15-deoxyspergualin inhibits natural antibody production but fails to prevent hyperacute rejection in a discordant xenograft model. Transplantation 1992; 54: 26.
14. MARCHMAN W, ARANEDA D, DEMASI R et al. Prolongation of xenograft survival after combination therapy with 15-deoxyspergualin and total-lymphoid irradiation in the hamster-to-rat cardiac xenograft model. Transplantation 1992; 53: 30.
15. GANNEDAHL G, KARLSSON-PARRA A, TOTTERMAN TH, TUFVESON G. 15-Deoxyspergualin inhibits antibody production in mouse to rat heart transplantation. Transplant Proc 1993; 25: 778.
16. REICHENSPURNER H, HUMAN PA, BOEHM DH et al. Optimalization of immunosuppression after xenogeneic heart transplantation in primates. J Heart Transplant 1989; 8: 200.
17. RAMOS EL, NADLER SG, GRASELA DM, KELLEY SL. Deoxyspergualin: mechanism of action and pharmacokinetics. Transplant Proc 1996; 28: 873.
18. ANDOINS C, DE FORNEL D, ANNAT J, DUTARTRE P. Tolerance in a rat cardiac allograft model after short-term treatment with LF 08-0299. Absence of clonal deletion and evidence of CD4+ suppressor cells. Transplantation 1996; 62: 1543.
19. BRULEY-ROSSET M, CHURAQUI E, ANNAT J, DUTARTRE P. LF 08-0299 protects murine recipients of minor antigen disparate donor bone marrow from lethal graft-versus-host disease. Transplant Proc 1996; 28: 3114.
20. ANNAT J, CHURAQUI E, DUTARTRE P, BRULEY-ROSSET M. Prevention of lethal graft-versus-host disease following allogeneic bone marrow transplantation in mice by short course administration of LF 08-0299. Transplantation 1996; 62: 721.
21. CHIOLEAU E, DUTARTRE P, USUAL C, SOULILLOU J-P, CUTURI M-C. Mechanisms of Induction of Allograft Tolerance in Rat by Short-term Treatment with LF 15-0195. American Journal of Transplantation 2001; 1(suppl 1): 167.
22. WANG H, DEVRIES ME, DENG S et al. The axis of interleukin 12 and gamma interferon regulates acute vascular xenogeneic rejection. Nat Med 2000; 6: 549.
23. OLFERT ED, CROSS BM, MCWILLIAM AA. Responsibility for the care and use of experimental animals. In: OLFERT ED, CROSS BM, MCWILLIAM AA, eds. Guide to the Care and Use of Experimental Animals, Vol. 1. Ottawa: Association of Universities and Colleges of Canada, 1993, pp. 1.
24. CORRY RJ, WINN HJ, RUSSELL PS. Primary vascularized allograft of hearts in mice. Transplantation 1973; 16: 343.
25. ZHANG Z, ZHU L, QUAN D et al. Pattern of liver, kidney, heart, and intestine allograft rejection in different mouse strain combinations. Transplantation 1996; 62: 1267.
26. BINDER J, LEHMANN M, GRASER E et al. The effect of non-depleting CD4 targeted therapy in presensitized rat recipients of cardiac allografts. Transplantation 1996; 61: 804.
27. ONODERA K, LEHMANN M, AKALIN E et al. Induction of 'infectious' tolerance to MHC-incompatible cardiac allografts in CD4 mAb-treated sensitized rat recipients. J Immunol 1996; 157: 1944.
28. WANG H, ROLLINS S, GAO Z et al. Complement inhibition with an anti-C5 monoclonal antibody prevents hyperacute rejection in a xenograft heart transplantation model. Transplantation 1999; 68: 1643.
29. AUCHINCLOSS HJ, SACHS DH. Xenogeneic transplantation. Annu Rev Immunol 1998; 16: 433.
30. VAN DEN BOGAERDE, WHITE DJ. Xenogeneic transplantation. Br Med Bull 1997; 53: 904.
31. LEVENTHAL JR, MATAS AJ, SUN LH et al. The immunopathology of cardiac xenograft rejection in the guinea pig-to-rat model. Transplantation 1993; 56: 1.
32. STEIBRUCHEL DA. Pathogenesis and mechanisms of graft rejection in concordant xenotransplantation with special reference to hamster-to-rat cardiac transplantation. APMIS 1996; 104: 1.
33. PLATT JL. New directions for organ transplantation. Nature 1998; 392: 11.
34. SATO K, TAKIGAMI K, MIYATAKE T et al. Suppression of delayed xenograft rejection by specific depletion of elicited antibodies of the IgM isotype. Transplantation 1999; 68: 844.
35. INVERARDI L, PARDI R. Early events in cell-mediated recognition of vascularized xenografts: cooperative interactions between selected lymphocyte subsets and natural antibodies. Immunol Rev 1994; 141: 71.
36. BLAKELY ML, VAN DER WERF WJ, BERNDT MC, DALMASSO AP, BACH FH, HANCOCK WW. Activation of intragraft endothelial and mononuclear cells during discordant xenograft rejection. Transplantation 1994; 58: 1059.
37. BACH FH, ROBSON SC, WINKLER H et al. Barriers to xenotransplantation. Nat Med 1995; 1: 869.
38. GALILI U. Anti-αgalactosyl (anti-gal) antibody damage beyond hypcracute rejection. In: COOPER DKC, KEMP E, PLATT JL, WHITE DJG, eds. Xenotransplantation: The Transplantation of Organs and Tissues Between Species. Berlin: Springer, 1997, pp. 95.
39. GALILI U, MINANOV OP, MICHLER RE, STONE KR. High affinity anti-Gal immunoglobulin G in chronic rejection of xenografts. Xenotransplantation 1997; 4: 127.
40. LEBRETON L, ANNAT J, DERREPAS P, DUTARTRE P, RENAUT P. Structure-immunosuppressive activity relationships of new analogues of 15-deoxyspergualin. 1. Structural modifications of the hydroxyglycine moiety. J Med Chem 1999; 42: 277.
41. ZHOU D, O'BRIEN C, GARCIA B et al. LF 15-0195. A Novel Immunosuppressive Agent Prevents Rejection and Induces Tolerance in a Mouse Cardiac Allograft Model. American Journal of Transplantation 2001; 1 (suppl 1): 437.
42. TANABE K, TAKAHASHI K, NEMOTO K et al. Effect of deoxyspergualin on vascular rejection in canine kidney transplantation. J Urol 1994; 152: 562.
43. SEBILLE F, GUILLET M, BROUARD S et al. T-cell-mediated rejection of vascularized xenografts in the absence of induced anti-donor antibody response. Am J Transplantation 2001; 1: 21.
44. STERBENZ KG, TEPPER MA. Effects of 15-deoxyspergualin on the expression of surface immunoglobulin in 70Z/3.12 murine pre-B cell line. Ann N Y Acad Sci 1993; 685: 205.
45. TEPPER MA, NADLER SG, ESSELSTYN JM, STERBENZ KG. Deoxyspergualin inhibits kappa light chain expression in 70Z/3 pre-B cells by blocking lipopolysaccharide-induced NF-kappa B activation. J Immunol 1995; 155: 2427.
46. THANOS D, MANIATIS T. NF-kappa B: a lesson in family values. Cell 1995; 80: 529.
47. PLATT JL, LINDMAN BJ, GELLER RL et al. The role of natural antibodies in the activation of xenogenic endothelial cells. Transplantation 1991; 52: 1037.
48. LEVENTHAL JR, DALMASSO AP, CROMWELL JW et al. Prolongation of cardiac xenografts survival by depletion of complement. Transplantation 1993; 55: 857.
49. HANCOCK WW, BLAKELY ML, VAN DER WERF W, BACH FH. Rejection of guinea pig cardiac xenografts post-cobra venom factor therapy is associated with infiltration by mononuclear cells secreting interferon-gamma and diffuse endothelial activation. Transplant Proc 1993; 25: 2932.
50. FRYER JP, LEVENTHAL JR, DALMASSO AP et al. Cellular rejection in discordant xenografts when hyperacute rejection is prevented: analysis using adoptive and passive transfer. Transpl Immunol 1994; 2: 87.
51. LIN Y, VANDEPUTTE M, WAER M. Natural killer cell- and macrophage-mediated rejection of concordant xenograft in the absence of T and B cell responses. J Immunol 1997; 158: 5658.
52. FRYER JP, LEVENTHAL JR, DALMASSO AP et al. Beyond hyperacute rejection. Accelerated rejection in a discordant xenograft model by adoptive transfer of specific cell subsets. Transplantation 1995; 59: 171.